X

Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot

—  Sarepta Therapeutics, Inc.  (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.

— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.

— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.

— SRPT shares ended Wednesday’s regular trading session down 1.14%. 

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Related Post